The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 12,012.00
Ask: 12,016.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.033%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

India's vaccine output likely to fall short of target, sources say

Thu, 20th May 2021 13:14

By Neha Arora and Krishna N. Das

NEW DELHI, May 20 (Reuters) - India's output of COVID-19
shots for August-December is likely to be lower than the
government's public estimate, according to internal projections
shared with Reuters by two sources.

Lower-than-expected production could delay India's plans to
vaccinate all its adults this year, amid fears the country will
face another surge of coronavirus infections in the winter.
India's ongoing second wave, the world's worst since the
pandemic began, has overwhelmed its health system.

The government last week publicly estimated 1.46 billion
doses of its three approved shots - AstraZeneca, Sputnik
V and Covaxin - would be made between August and December.

Production of the AstraZeneca vaccine, of which the Serum
Institute of India (SII) is the biggest maker in the world, is
expected to reach 100 million to 110 million doses a month from
July and stay at that level for the foreseeable future, a source
with knowledge of the matter said.

That would be at least 200 million doses less than the
government's public forecast of 750 million AstraZeneca doses
for the last five months of the year, a 27% shortfall.

An internal government projection for August and September
shared by a second source put the monthly number of AstraZeneca
doses at 100 million, out of 200 million for all the three
approved shots combined.

The sources declined to be named discussing a subject on
which Prime Minister Narendra Modi's government has been
criticised due to a shortage of vaccines. Immunisations have
fallen https://dashboard.cowin.gov.in sharply since an April
peak.

The Ministry of Health and Family Welfare did not respond to
queries from Reuters.

SII, which is facing raw material shortages for another
vaccine that the government is banking on, declined to comment.

A spokeswoman for Covaxin-maker Bharat Biotech said that
last month the company raised its annual production capacity to
more than 500 million doses, or about 42 million doses a month.
It has been producing about 10 million doses a month.

Dr. Reddy's Laboratories, the local distributor
for Russia's Sputnik V, did not respond to a request for
comment.

Apart from the approved vaccines, the government has also
forecast August-December production of 866 million doses of five
yet-to-be-approved vaccines. Overall, the government has pledged
to make 2.67 billion doses available this year.

SII has already halted exports until the end of the year to
meet domestic demand, in a major blow to dozens of poor
countries relying on it for supplies.

India has so far administered 187 million vaccine doses, the
most after China and the United States, but fully immunised only
about 3% of its 1.35 billion people.

(Reporting by Neha Arora and Krishna N. Das; editing by
Philippa Fletcher)

More News
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.